摘要
目的 探讨白蛋白紫杉醇对一线治疗失败后晚期食管癌患者的临床疗效。方法 一线治疗失败的晚期食管癌患者29例,采用白蛋白紫杉醇100~150mg/m2,第1、8天给药,21d为1个化疗周期;每2个治疗周期评价疗效及不良反应。结果 2例患者因出现不良反应而终止治疗。27例患者完成治疗;其中,部分缓解10例,疾病稳定2例,疾病进展15例;客观缓解率37.0%,疾病控制率44.4%,无疾病进展生存期为6.6个月。主要不良反应为脱发18例（62.1%）,中性粒细胞减少19例（65.5%）,消化道反应4例（13.8%）和周围神经毒性2例（6.9%）。结论 白蛋白紫杉醇在经过多线抗肿瘤治疗后的晚期食管癌治疗中仍显示出一定疗效,且不良反应可以耐受。
Objective To evaluate the efficacy of albumin-bound paclitaxel-based chemotherapy strategy in the treatment of advanced esophageal cancer failled to the first-line therapy. Methods The chemotherapy with albumin-bound paclitaxel 100-150 mg/m2 on the 1st, 8th day for 21 days （ one treatment cycle） was used in 29 advanced esophageal cancer patients failled to the first-line therapy. The efficacy and adverse effects were evaluated every two treatment cycles. Results The treamlent was interrupted in 2 patients because of adverse effects. Twenty-seven cases completed the treatment, of whom 10 patients achieved partial response, 2 cases remained stable disease, and 15 cases had progressive disease. The objective response rate was 37.0% and the disease control rate was 44.4%. The median survival time for disease-free progression was 6.6 months. The major adverse effects included alopecia in 18 cases （62.1%）, neutropenia in 19 cases （65.5 %）, gastrointestinal reaction in 4 cases（13.8%） and sensory neuropathy in 2 cases （6.9%）. Conclusion The albumin-bound paclitaxel-based chemotherapy strategy is effective and safe in the treatment of the patients with advanced esophageal cancer failed to the first-line chemotherapy.
出处
《江苏医药》
CAS
2016年第3期298-299,302,共3页
Jiangsu Medical Journal
基金
吴阶平基金(320.6750.13231)
关键词
白蛋白紫杉醇
食管癌
化疗
Albumin-bound paclitaxel
Esophageal cancer
Chemotherapy
